On October 1st, Pfizer decided to reduce prices on certain medications as a result of President Donald Trump’s executive order regarding the most-favored-nation drug pricing.
This order presents potential penalties like price caps for Medicare and Medicaid, restrictions on exports, and the possibility of revoking approvals for medications if companies fail to lower U.S. prices to match those abroad. Just days prior, President Trump warned of imposing 100 percent tariffs on pharmaceutical companies that do not manufacture products domestically.
While the goals of making medicines cheaper and strengthening the U.S. industry are commendable, these policies might lead to unintended negative consequences. The risks could include diminished access to new treatments and potential harm to the domestic industry that Trump aims to bolster.
It’s understandable that the president is frustrated—Americans often pay significantly more for medications than those in other countries, sometimes double the cost, largely due to different public insurance frameworks. Other countries negotiate prices effectively, leveraging bulk purchasing to drive down costs.
In contrast, the Centers for Medicare and Medicaid Services (CMS) in the U.S. does not legally negotiate prices for many drugs, limiting flexibility. Starting in 2026, CMS will be restricted further under the Inflation Control Act, typically paying fixed prices. This approach could lead to higher costs for private patients and insurance companies, as companies respond by raising prices generally.
This situation isn’t without some advantages. The pharmaceutical industry does yield substantial profits in the U.S., which enables access to cutting-edge products and treatments. However, if companies are pressured to lower prices, it might jeopardize research, new innovations, and jobs that depend on those profits.
What would be more beneficial is if other countries contributed their fair share. Research and development for new drugs incur immense costs—billions are spent on testing and obtaining approvals, and potential profits from existing products are essential to fund new projects.
If there’s less money flowing into research, the number of treatments available, job opportunities, and the production of affordable generic drugs will all decline. Some studies even suggest that stringent price controls could lead to significant drops in newly approved drugs over time.
Additionally, managing prices frequently leads to shortages and decreased access to healthcare. Artificially lowering drug prices could force rural providers to shut down due to decreased reimbursements.
While convincing other nations to increase their drug prices won’t be easy, it is certainly achievable. The U.S., as a major economic power and a leader in lifesaving treatments, holds substantial influence.
Global agreements to raise drug prices could ensure that U.S. innovations don’t disproportionately support other nations at the expense of American citizens. A multilateral framework on drug pricing could allow discussions to set international reference prices for patented medications, adjusted to each nation’s economic capabilities, potentially easing the financial burden on Americans.
Domestically, Trump’s “Trump Rx” initiative, aimed at connecting Americans to discounted medications, seems like a positive step.
On the deregulation front, strategies to lower domestic prices could include allowing hospitals to purchase drugs at lower costs or permitting interstate insurance buying. Additionally, streamlining approval processes and relaxing restrictions on imports could help.
While imposing a 100 percent tariff might foster some domestic manufacturing, thereby creating jobs, it might also exact a high cost in terms of innovation. Trade and regulatory reforms would likely yield more favorable results on drug pricing without stifling progress.
